Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
Introduction: Standard treatment with cyclophosphamide (CP) or rituximab (RTX) is suboptimal. We adapted and used the low-dose regimen used in vasculitis (RTX 2 × 1000 mg, CP 1.5 mg/kg/d × 8 weeks, and prednisone [i.v. 2 × 1 g + 3 weeks oral starting at 1 mg/kg]). Methods: High-risk, anti-PLA2R anti...
Saved in:
| Main Authors: | Coralien H. Vink, Jack F.M. Wetzels, Anne-Els van de Logt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924019211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differences in serum anti-PLA2R antibody determination in Uygur patients with idiopathic membranous nephropathy in Xinjiang
by: ZHANG Jin, et al.
Published: (2018-01-01) -
Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy
by: Suruthy Narayanasami, et al.
Published: (2024-05-01) -
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01) -
Concurrent IgG4-related membranous nephropathy and proliferative diabetic kidney disease: a diagnostic dilemma and therapeutic strategy in long-standing diabetes
by: Yue Yang, et al.
Published: (2025-07-01) -
Association of two polymorphisms rs3749117 and rs3749119 in PLA2R1 with idiopathic membranous nephropathy:A Meta-analysis
by: Sheng Qian, et al.
Published: (2021-01-01)